3 completed, 2 recruiting, 1 terminated. 6 Phase 2, 1 Phase 1, 1 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 6 | Completed 3, Recruiting 2, Terminated 1 |
| Phase 1 | 1 | Completed 1 |
| Phase 3 | 1 | Recruiting 1 |
Follow Schizophrenia, Treatment-Resistant: new trials by email Literature Review of Schizophrenia, Treatment-Resistant trials Research Report on Schizophrenia, Treatment-Resistant
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| The Effectiveness and Efficacy of the Combination of the Integrated Psychological Therapy and Metacognitive Training. The combination of the Integrated Psychological Therapy and Metacognitive Training in individuals with schizophrenia and treatment resistant schizophrenia - Schizophrenia | Phase 2 | Completed | Rakitzi, Stavroula | 35 | 2022-11-01 | 2025-03-05 |
| Neurotransmitters in Treatment Resistant Schizophrenia Patients With add-on Sodium Benzoate Sodium Benzoate 2gram/day, Placebo - Symptom, Cognitive, Schizophrenia | Phase 2 | Recruiting | National Cheng-Kung University Hospital | 90 | 2021-11-18 | 2026-06-16 |
| Rituximab for Schizophrenia Spectrum Disorder (RITS-PS-2019) Rituximab - Schizophrenia Spectrum and Other Psychotic Disorders, Treatment-resistant Schizophrenia | Phase 2 | Completed | Region Örebro County | 9 | 2019-08-07 | 2025-03-21 |
| Telmisartan Pilot Study on Treatment Resistant Schizophrenia Telmisartan Pill - Schizophrenia, Schizo Affective Disorder | Phase 2 | Terminated | Xiaoduo Fan | 6 | 2019-02-01 | 2022-03-02 |
| An Adaptive Phase II/III, Two-Part, Double-Blind, Randomized, Placebo-controlled, Dose-Finding, Multi-center Study of the Safety and Efficacy of NaBen®, as an Add-on Therapy With Clozapine, for Residual Symptoms of Refractory Schizophrenia in Adults NaBen®, Placebo - Refractory Schizophrenia | Phase 2 / Phase 3 | Recruiting | SyneuRx International (Taiwan) Corp | 287 | 2017-03-29 | 2021-09-13 |
| Clozapine-induced Hypersalivation - Feasibility Trial Hyoscine, Glycopyrrolate, Placebo - Sialorrhea | Phase 1 / Phase 2 | Completed | Mersey Care NHS Trust | 29 | 2016-01-25 | 2018-02-28 |
Schizophrenia (3) · Psychotic Disorders (2) · Neurobehavioral Manifestations (1) · Schizophrenia Spectrum and Other Psychotic Disorders (1) · Sialorrhea (1)
Mental Disorders (6) · Schizophrenia Spectrum and Other Psychotic Disorders (5) · Schizophrenia (3) · Mouth Diseases (1) · Nervous System Diseases (1) · Neurologic Manifestations (1) · Pathological Conditions, Signs and Symptoms (1) · Salivary Gland Diseases (1) · Signs and Symptoms (1) · Stomatognathic Diseases (1)
Butylscopolammonium Bromide (1) · Drug Therapy (1) · Glycopyrrolate (1) · Rehabilitation (1) · Rituximab (1) · Scopolamine (1) · Telmisartan (1)
Mersey Care NHS Trust (1) · National Cheng-Kung University Hospital (1) · Rakitzi, Stavroula (1) · Region Örebro County (1) · SyneuRx International (Taiwan) Corp (1) · Xiaoduo Fan (1)
United States (2) · Greece (1) · Sweden (1) · Taiwan (1) · United Kingdom (1)
Inti Qurashi, MBChB (1) · Stavroula Rakitzi, Dr. (1) · Susanne Bejerot (1) · Xiaoduo Fan, MD, MPH (1) · Yen-Kuang Yang, Dr (1)
PMID 10473315, PMID 27280523, PMID 27871302, PMID 31236286, PMID 36638622, PMID 39350952